[go: up one dir, main page]

MX2019002959A - Inhibidores biciclicos condensados de la interaccion de menina-mll. - Google Patents

Inhibidores biciclicos condensados de la interaccion de menina-mll.

Info

Publication number
MX2019002959A
MX2019002959A MX2019002959A MX2019002959A MX2019002959A MX 2019002959 A MX2019002959 A MX 2019002959A MX 2019002959 A MX2019002959 A MX 2019002959A MX 2019002959 A MX2019002959 A MX 2019002959A MX 2019002959 A MX2019002959 A MX 2019002959A
Authority
MX
Mexico
Prior art keywords
inhibitors
menina
mll interaction
condensed
condensed bicycle
Prior art date
Application number
MX2019002959A
Other languages
English (en)
Other versions
MX389598B (es
Inventor
Alexis Georges Querolle Olivier
Pande Vineet
Herkert Barbara
Jason Krosky Daniel
Nathaniel Patrick Aaron
René Angibaud Patric
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019002959A publication Critical patent/MX2019002959A/es
Publication of MX389598B publication Critical patent/MX389598B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a agentes farmaceuticos utiles para tratamiento y/o profilaxis en un mamifero, y en particular a compuestos biciclicos condensados, composición farmaceutica que comprende dichos compuestos, y su uso como inhibidores de la interaccion de proteina/proteina menina/MLL, utiles para tratar enfermedades tales como cancer, síndrome mielodisplasico (MDS) y diabetes.
MX2019002959A 2016-09-14 2017-09-13 Inhibidores bicíclicos condensados de la interacción de menina-mll. MX389598B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662394291P 2016-09-14 2016-09-14
EP16192424 2016-10-05
EP17180228 2017-07-07
PCT/EP2017/073001 WO2018050684A1 (en) 2016-09-14 2017-09-13 Fused bicyclic inhibitors of menin-mll interaction

Publications (2)

Publication Number Publication Date
MX2019002959A true MX2019002959A (es) 2019-07-04
MX389598B MX389598B (es) 2025-03-11

Family

ID=59901513

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002959A MX389598B (es) 2016-09-14 2017-09-13 Inhibidores bicíclicos condensados de la interacción de menina-mll.

Country Status (13)

Country Link
US (2) US10611778B2 (es)
EP (1) EP3512858B1 (es)
JP (1) JP7033141B2 (es)
KR (1) KR102493364B1 (es)
CN (1) CN109715634B (es)
AU (1) AU2017326485B2 (es)
CA (1) CA3033020A1 (es)
ES (1) ES2966316T3 (es)
IL (1) IL265231B (es)
MA (1) MA46228A (es)
MX (1) MX389598B (es)
TW (1) TWI753016B (es)
WO (1) WO2018050684A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
SMT202300273T1 (it) 2016-03-16 2023-09-06 Kura Oncology Inc Derivati di tieno[2,3–d]pirimidina sostituiti come inibitori di menina–mll e metodi d’uso
MA43823A (fr) 2016-03-16 2018-11-28 Kura Oncology Inc Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
JP7142010B2 (ja) 2016-12-15 2022-09-26 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のアゼパン阻害剤
CN117298275A (zh) 2017-03-24 2023-12-29 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN112105621B (zh) * 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
CA3108449A1 (en) * 2018-08-08 2020-02-13 Sumitomo Dainippon Pharma Co., Ltd. Optically active bridged piperidine derivative
EP3845533A4 (en) * 2018-08-27 2022-04-27 Sumitomo Dainippon Pharma Co., Ltd. OPTICALLY ACTIVE AZABICYCLIC DERIVATIVE
EP3892278B1 (en) 2018-12-06 2024-02-28 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
JOP20220154A1 (ar) 2019-12-19 2023-01-30 Janssen Pharmaceutica Nv مشتقات سبيرو بسلسلة مستقيمة بها استبدال
CN114516873A (zh) * 2020-11-18 2022-05-20 苏州优理生物医药科技有限公司 一种螺环类化合物、包含其药物组合物及其应用
KR20230142745A (ko) 2021-01-29 2023-10-11 세딜라 테라퓨틱스, 인크. Cdk2 억제제 및 그의 사용 방법
JP2024518425A (ja) 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換スピロ誘導体
CN117321049A (zh) 2021-05-08 2023-12-29 詹森药业有限公司 取代的螺环衍生物
CR20230605A (es) 2021-06-01 2024-05-24 Janssen Pharmaceutica Nv Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos
BR112023025436A2 (pt) 2021-06-03 2024-02-27 Janssen Pharmaceutica Nv Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
PH12023553300A1 (en) 2021-06-17 2024-04-08 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
TW202317560A (zh) 2021-06-26 2023-05-01 美商賽迪拉治療股份有限公司 Ｃｄｋ２抑制劑及其使用方法
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
EP4622635A1 (en) 2022-11-24 2025-10-01 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
PL372145A1 (en) 2002-02-19 2005-07-11 Cv Therapeutics, Inc. Partial and full agonists of a sb 1 /sb adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
CA2509406C (en) * 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
EP1753428A4 (en) * 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
AU2006206738A1 (en) * 2005-01-19 2006-07-27 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
TWI389913B (zh) * 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
JP2011026305A (ja) * 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
EP2473054B1 (en) * 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CN103664991B (zh) * 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
WO2014100730A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
SI2935222T1 (sl) 2012-12-21 2019-02-28 Epizyme Inc. Inhibitorji PRMT5 in njihove uporabe
US9216993B2 (en) * 2013-03-13 2015-12-22 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2015191701A1 (en) 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016081732A1 (en) 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
CN108779116A (zh) 2015-12-22 2018-11-09 生命医药公司 多发性内分泌瘤蛋白-mll相互作用的抑制剂
MA43823A (fr) 2016-03-16 2018-11-28 Kura Oncology Inc Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation
SMT202300273T1 (it) 2016-03-16 2023-09-06 Kura Oncology Inc Derivati di tieno[2,3–d]pirimidina sostituiti come inibitori di menina–mll e metodi d’uso
SG11201809714TA (en) 2016-05-02 2018-11-29 Univ Michigan Regents Piperidines as menin inhibitors
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
KR20250079083A (ko) 2016-06-10 2025-06-04 비타이 파마슈티컬즈, 엘엘씨 메닌-mll 상호 작용의 억제제
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CN109689663B (zh) * 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
MX2019003091A (es) 2016-09-16 2019-07-08 Vitae Pharmaceuticals Inc Inhibidores de la interaccion de menina-mll.
EA201990699A1 (ru) 2016-10-05 2019-09-30 Янссен Фармацевтика Нв Спиробициклические ингибиторы взаимодействия менин–mll
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
CN117298275A (zh) 2017-03-24 2023-12-29 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法

Also Published As

Publication number Publication date
CN109715634B (zh) 2022-09-27
US20190218230A1 (en) 2019-07-18
EP3512858B1 (en) 2023-11-08
JP2019530745A (ja) 2019-10-24
US20200172556A1 (en) 2020-06-04
BR112019004764A2 (pt) 2019-05-28
KR102493364B1 (ko) 2023-01-27
WO2018050684A1 (en) 2018-03-22
CN109715634A (zh) 2019-05-03
EP3512858C0 (en) 2023-11-08
MX389598B (es) 2025-03-11
MA46228A (fr) 2019-07-24
AU2017326485B2 (en) 2021-04-22
US10611778B2 (en) 2020-04-07
CA3033020A1 (en) 2018-03-22
JP7033141B2 (ja) 2022-03-09
TW201823249A (zh) 2018-07-01
IL265231A (en) 2019-05-30
ES2966316T3 (es) 2024-04-19
EP3512858A1 (en) 2019-07-24
KR20190046888A (ko) 2019-05-07
IL265231B (en) 2021-06-30
AU2017326485A1 (en) 2019-02-21
TWI753016B (zh) 2022-01-21
US10975100B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
MX2019002959A (es) Inhibidores biciclicos condensados de la interaccion de menina-mll.
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
EA201990699A1 (ru) Спиробициклические ингибиторы взаимодействия менин–mll
MX2018015252A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
CO2017011484A2 (es) Inhibidores de bromodominio
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
BR112018012707A2 (pt) inibidores da interação de menin-mll
CU24498B1 (es) Anticuerpos de factor xi
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
CR20170388A (es) Heterociclos biciclicos como inhibidores de fgdr4
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
EA201690159A1 (ru) Способы и композиции для лечения рака
MX2017003211A (es) Anticuerpos anti-met y composiciones.
CL2016001409A1 (es) Inhibidores de quinasa relacionada con la tropomiosina (trk).
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX377089B (es) Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral.
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
PE20170287A1 (es) Anticuerpos anti-proteina similar a angiopoyetina 4 y metodos de uso